腾讯网15 天
潜在“best-in-class”基因疗法积极2期临床结果公布，改善致盲疾病 ...
参考资料： [1] Beacon Therapeutics Announces Positive 3-Month Data from Phase 2 DAWN Trial of laru-zova (AGTC-501) in Patients with X-Linked Retinitis Pigmentosa (XLRP). Retrieved December 6 ...